Chromium picolinate does not produce chromosome damage

Area of Science:

• Toxicology
• Genetics
• Nutritional Science

Background:

• Chromium picolinate (CrPic) is a dietary supplement used for its potential benefits in managing diabetes risk factors.
• Understanding the cytogenetic effects of CrPic is crucial for assessing its safety profile.

Purpose of the Study:

• To evaluate the potential cytogenetic effects of chromium picolinate (CrPic) in the bone marrow cells of Sprague-Dawley rats.
• To determine if CrPic induces chromosomal damage at single oral doses.

Main Methods:

• Sprague-Dawley rats (5/sex/group) were administered single oral doses of CrPic (33, 250, or 2000 mg/kg).
• Bone marrow cells were analyzed for chromosomal aberrations at 18 and 42 hours post-administration.
• A positive control (Cyclophosphamide) was used to validate the assay's sensitivity.

Main Results:

• No statistically significant increase in chromosomal damage was observed in rats treated with CrPic compared to vehicle controls at either time point.
• The positive control, Cyclophosphamide, induced significant chromosomal damage, confirming the assay's validity.
• The highest dose of CrPic (2000 mg/kg) showed a slight increase in damage in males at 42h, but this was not statistically significant.

Conclusions:

• Single oral administration of chromium picolinate did not induce chromosomal damage in rat bone marrow cells.
• The findings suggest that CrPic does not exhibit genotoxic potential at the tested doses.
• This study provides evidence supporting the safety of CrPic regarding chromosomal integrity.